RecruitingNCT06640010
Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events
Sponsor
Mayo Clinic
Enrollment
30 participants
Start Date
Jan 13, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Any patient >= 18 years of age
- Previously treated, planned or currently receiving any potentially toxic cancer therapy including but not limited to chemotherapy, targeted and immunotherapies
Exclusion Criteria1
- Inability on the part of the patient to understand the informed consent or be compliant with the protocol
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06640010
Related Trials
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
NCT0569149123 locations
Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
NCT037502274 locations
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT0699589837 locations
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
NCT009910941 location
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT0381634552 locations